Journal of Clinical Oncology, Vol 15, 1302-1308, Copyright © 1997 by American Society of Clinical Oncology
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results
M Legros, J Dauplat, J Fleury, H Cure, F Suzanne, J Chassagne, JO Bay, C Sol, M Canis, P Condat, B Choufi, F Tavernier, C Glenat, P Chollet and R Plagne
Centre Jean Perrin, Clermont-Ferrand, France.
PURPOSE: A series of 53 patients with poor-prognosis epithelial ovarian
cancer treated with high-dose chemotherapy (HDC) followed by hematopoietic
rescue was retrospectively studied from the day of diagnosis for toxicity
and long-term survival analysis. PATIENTS AND METHODS: Patients were
treated with surgery followed by cisplatin combination chemotherapy. After
second-look operation (SLO), HDC was administered: 23 patients received
melphalan (140 mg/m2 on day 1) and 30 patients received a combination of
carboplatin (400 mg/m2 on days 1 to 4) and cyclophosphamide (1.6 g/m2 on
days 1 to 4). After HDC, autologous stem-cell transplantation was performed
for hematologic support. RESULTS: One patient died of cardiac failure after
HDC, but the acute toxicity was acceptable for the other patients. With a
median follow-up of 81.5 months, the 5-year overall survival rate for the
53 patients was 59.9% and the disease-free survival (DFS) rate at 5 years
was 23.6%. Twenty-four patients (45.3%) were alive, 12 with no evidence of
disease and 12 with recurrent disease. The best results were achieved in 19
patients with pathologic complete response at SLO (74.2% 5-year overall
survival; 32.8% 5-year DFS). CONCLUSION: HDC followed by autologous
stem-cell support is a well-tolerated therapeutic approach for patients
with poor-prognosis ovarian carcinoma. In this report, the 59.9% survival
of 53 patients at 5 years must be compared to the 20% to 30% 5-year
survival observed after conventional therapy. These results should be
confirmed by an ongoing prospective randomized trial.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
V. Mobus, H. Wandt, N. Frickhofen, C. Bengala, K. Champion, R. Kimmig, H. Ostermann, A. Hinke, and J. A. Ledermann
Phase III Trial of High-Dose Sequential Chemotherapy With Peripheral Blood Stem Cell Support Compared With Standard Dose Chemotherapy for First-Line Treatment of Advanced Ovarian Cancer: Intergroup Trial of the AGO-Ovar/AIO and EBMT
J. Clin. Oncol.,
September 20, 2007;
25(27):
4187 - 4193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Pedrazzoli, J. Ledermann, J-P Lotz, S Leyvraz, M Aglietta, G Rosti, K. Champion, S Secondino, F Selle, N Ketterer, et al.
High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults
Ann. Onc.,
October 1, 2006;
17(10):
1479 - 1488.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Navo and J. A. Smith
Update on the Prevention and Treatment of Ovarian Cancer
Journal of Pharmacy Practice,
June 1, 2003;
16(3):
149 - 156.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. A. Bookman
Developmental Chemotherapy and Management of Recurrent Ovarian Cancer
J. Clin. Oncol.,
May 15, 2003;
21(90100):
149s - 167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Strother, D. Ashley, S. J. Kellie, A. Patel, D. Jones-Wallace, S. Thompson, R. Heideman, E. Benaim, R. Krance, L. Bowman, et al.
Feasibility of Four Consecutive High-Dose Chemotherapy Cycles With Stem-Cell Rescue for Patients With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor After Craniospinal Radiotherapy: Results of a Collaborative Study
J. Clin. Oncol.,
May 15, 2001;
19(10):
2696 - 2704.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Scheulen, R. A. Hilger, C. Oberhoff, J. Casper, M. Freund, K. M. Josten, M. Bornhauser, G. Ehninger, W. E. Berdel, J. Baumgart, et al.
Clinical Phase I Dose Escalation and Pharmacokinetic Study of High-Dose Chemotherapy with Treosulfan and Autologous Peripheral Blood Stem Cell Transplantation in Patients with Advanced Malignancies
Clin. Cancer Res.,
November 1, 2000;
6(11):
4209 - 4216.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Stiff, J. Veum-Stone, H. M. Lazarus, L. Ayash, J. R. Edwards, A. Keating, J. P. Klein, D. J. Oblon, T. C. Shea, S. Thome, et al.
High-Dose Chemotherapy and Autologous Stem-Cell Transplantation for Ovarian Cancer: An Autologous Blood and Marrow Transplant Registry Report
Ann Intern Med,
October 3, 2000;
133(7):
504 - 515.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Markman and M. A. Bookman
Second-Line Treatment of Ovarian Cancer
Oncologist,
February 1, 2000;
5(1):
26 - 35.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. J. Schilder, S. Johnson, J. Gallo, S. Kindsfather, B. Rogers, M. A. Bookman, M. M. Millenson, M. Boente, N. Rosenblum, S. Litwin, et al.
Phase I Trial of Multiple Cycles of High-Dose Chemotherapy Supported by Autologous Peripheral-Blood Stem Cells
J. Clin. Oncol.,
July 1, 1999;
17(7):
2198 - 2198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Makatsoris and M. V. Seiden
High-Dose Therapy for Ovarian Carcinoma
Oncologist,
October 1, 1997;
2(5):
330 - 339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
